Nvidia’s artificial intelligence ambitions in medicine and healthcare become clearer | Wilnesh News

last week, Nvidia announced an agreement with Johnson & Johnson to use generative artificial intelligence in surgery, and Partner with GE Healthcare to improve medical imaging. Healthcare advancements at the 2024 GTC AI conference — which also include the launch of about two dozen new AI-powered, healthcare-focused tools — show just how important pharmaceuticals will be to Nvidia’s future non-tech revenue opportunities.

“The reason Nvidia is so popular today is because it basically provides the pipeline and technology for things that you couldn’t do before, or if you had to do something like this, it would take you multiple times the time, money and cost,” Moody’s said Raj Joshi, Ratings technical analyst and senior vice president. “Healthcare, whether it’s biotech, chemicals or drug discovery is a very strong area.”

Nvidia shares are up nearly 100% so far this year, and the biotech industry is an example of the untapped potential that investors continue to bet on. Artificial intelligence can speed up the drug discovery process and even find uses for drugs that may not produce results for the diseases they were originally developed for.

Arda Ural said: “Over the past 18 months or so, we have tended to believe that this is more hope than hype, because there are tangible results and how artificial intelligence can help the pharmaceutical industry, the medical technology industry or the biotech industry. A very compelling use case for the industry.” Ernst & Young Americas market leader for the health and life sciences industry.

Ural said drug development is a dangerous process and can take at least a decade from concept to clinical studies. It’s also a process that can cost billions of dollars, and the potential for failure is high.

Some 41% of biotech CEOs surveyed by Ernst & Young in late 2023 said they were looking for “concrete” ways to use generative artificial intelligence in their companies. “That’s very high considering my 30 years of experience in this industry,” Ural said. “This is a very unique capability that we’re seeing in artificial intelligence, and it’s being adopted much faster than other technologies.”

Nvidia’s focus on healthcare at its conference doubles down on its long-standing ambitions. During an earnings call with investors in February, Nvidia mentioned several ways its technology could fit into the medical field.company likes Return Pharmaceutical and generation: Biomedical sciences have been scaling up their biomedical research with the help of hyperscale or GPU-specific cloud providers, and they need Nvidia AI infrastructure to facilitate this process.

“In healthcare, digital biology and generative artificial intelligence are helping to reshape drug discovery, surgery, medical imaging and wearable devices,” said Colette Kress, chief financial officer at Nvidia. “Over the past decade, we have accumulated deep experience in healthcare. expertise to create the NVIDIA Clara Healthcare Platform and NVIDIA BioNeMo, a generative AI service for developing, customizing and deploying AI-based models for computer-assisted drug discovery.”

Last year, NVIDIA invested $50 million in Recursion for its drug discovery program. Recursion is feeding its biological and chemical data to train NVIDIA’s AI models on its cloud platform.The company also works with Roche Genentech Develop new drugs and better treatments.It will also be launched in 2021 with Schrödinger for drug discovery.

One of NVIDIA’s biggest healthcare advantages to date is the BioNeMo platform, a generative AI cloud service designed for drug development.

“It’s one thing to design semiconductors and computing platforms for others to do something. But it’s another thing entirely when you can build a mature technology package and sell it to customers,” Joshi said. “Let’s say you’re a biotech company and you get all the technology from Nvidia, and then you start working on it instead of figuring out ‘How do I use this information technology?'”

Biotech-focused generative artificial intelligence platforms have the ability to reduce costs for pharmaceutical companies outside of the drug development process. Many companies outsource supply chain, financial and administrative functions, and back-office processes of manufacturing to save money. But with geopolitical tensions rising and an emphasis on bringing jobs back to the United States, the costs of moving jobs overseas are growing.

“Now you can do it at home with artificial intelligence at a lower cost because you now have robotic process automation powered by artificial intelligence,” Ural said. “So not only does it help speed up drug development, but it also Helping reduce company operating costs. This means you can put more money into drug development and find more treatments faster.”

The healthcare sector is an example of how a company that designed gaming graphics cards a decade ago has become so accomplished. “You have to give them credit, Jensen had the foresight back in 2012 when he saw some people at Stanford actually using his graphics cards to solve certain types of math problems,” Joshi said. “He said, ‘You You know, this can actually be used to do so-called general-purpose computing, you know, things that we do every day.'”

But to fully realize the benefits of artificial intelligence in health care, leaders will need more support from one of the largest workforces in the United States. More than two-thirds of health sciences and healthcare employees are concerned about the use of AI, and seven in 10 are anxious about its adoption in the workplace, according to EY’s AI Business Anxiety Survey.